
Opinion|Videos|March 10, 2025
Drug Delivery Systems in NMIBC
Author(s)Karim Chamie, MD, MSHS
An expert discusses how non–muscle invasive bladder cancer (NMIBC) treatment involves evolving delivery systems, transitioning from traditional systemic and intravesical approaches to advanced targeted technologies. Current research focuses on innovative platforms such as nanoparticle carriers, thermosensitive hydrogels, and personalized molecular delivery mechanisms to improve therapeutic efficacy and minimize systemic toxicity.
Advertisement
Episodes in this series
Video content above is prompted by the following:
- Please provide a brief overview of delivery systems that are available to patients for treatment of NMIBC (ie, systemic IV delivery and bladder delivery systems).
- Discuss ongoing studies with investigational delivery systems in different subpopulations of NMIBC.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Urology Times
1
FDA approves lutetium Lu 177 vipivotide tetraxetan for PSMA-positive mHSPC
2
Testosterone deficiency: FAQs from the AUA guideline
3
Joshua Lang, MD, MS, on integrating molecular biomarkers into clinical practice
4
Large registry study reports durable 10-year outcomes with focal therapy for prostate cancer
5








